Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation
Tirzepatide significantly alleviates the severity of thoracic aortic aneurysm and dissection, aiding vascular health.
The study highlights a notable reduction in inflammatory markers associated with vascular smooth muscle deterioration.
Comprehensive analysis of vascular smooth muscle cells reveals the drug's role in preserving the contractile phenotype, crucial for vascular integrity.
Identifying therapeutic avenues in vascular inflammation could vastly improve outcomes for individuals with aortic conditions.